Sanofi, Regeneron Prepped PCSK9 Rollout with 'Cholesterol Counts' Campaign

Tuesday, December 1, 2015

Source: FiercePharma

No question that the marketing people at Sanofi ($SNY) were excited about alirocumab, the next-generation cholesterol drug that won approval earlier this year. Analysts had been talking about multibillion-dollar sales, and recent trial data--not just from Sanofi and its partner Regeneron ($REGN)--built optimism even further.

View All News »